What we are doing
The biological therapy audit's aim is to measure the efficacy, safety and appropriate use of biological therapies (Infliximab and Adalimumab) in patients with inflammatory bowel disease in the UK.
The audit aims to assess nationally:
- the appropriate use / prescribing of biological therapies (Adalimumab and Infliximab) in the treatment of IBD
- the efficacy of biological therapies in the treatment of IBD
- the safety of biological therapies in the treatment of IBD
- IBD patients' views on their quality of life at defined intervals throughout their use of biological therapies.
